Participants receiving semaglutide 2.4 mg once weekly lost an average of 15.3% of their starting body weight, while those on placebo lost only 2.6%
Hershey says demand for gum and mints is rising partly because of growing use of GLP-1 weight loss drugs
Cardio- and reno-protective effects are unlikely to be solely explained by the mechanisms used by these drugs to lower blood glucose levels, as the same effects are not seen with drugs that have stronger antihyperglycaemic actions [111], and were not dependent upon the degree of HbA1c reduction [113,114,115]
Understanding the medication itself is key to grasping why certain side effects, such as itching, occur
The STEP 1 trial studied semaglutide 2.4 mg in 1,961 adults with overweight or obesity, including some who had bariatric surgery